Searchable abstracts of presentations at key conferences in oncology

Oncology Abstracts

Published by BioScientifica
Volume 1 | PacRim7

7th International Pacific Rim (PacRim) Breast and Prostate Cancer Meeting


17 Mar 2019 - 20 Mar 2019

Card image cap

7th PacRim Meeting Poster Presentations

(1)

Table of contents

oa0001p001 | (1)

S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer

oa0001p002 | (1)

BMP4 is a bonafide breast cancer metastasis suppressor

oa0001p003 | (1)

Using coordination chemistry and nanotechnology to develop a brand new class of therapeutics

oa0001p004 | (1)

A GWAS identified functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer

oa0001p005 | (1)

Expression of the interleukin-3/receptor complex by breast cancer cells promotes vascular mimicry via a PI3K-dependent mechanism and is associated with poor outcome

oa0001p006 | (1)

ROCK educates cancer-associated fibroblasts via secreted Creld2 to create a tumour-promoting microenvironment

oa0001p007 | (1)

Estrogen receptor positive luminal progenitors the cancer cell origin for Estrogen receptor positive breast cancer

oa0001p008 | (1)

Mechanisms underlying uncontrolled genome doubling in breast cancer

oa0001p009 | (1)

Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer

oa0001p010 | (1)

Epi-transcriptomic alterations in ER-positive breast cancer

oa0001p011 | (1)

The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer

oa0001p012 | (1)

Targeting AR in endocrine-resistant breast cancer

oa0001p013 | (1)

Single cell transcriptome analysis reveals human prostate cancer cells upregulate retinoic acid signalling in response to androgen withdrawal

oa0001p014 | (1)

Nuclear ErbB-2 activity modulates the interferon signaling pathway in breast cancer cells resistant to anti-ErbB-2 therapies

oa0001p015 | (1)

Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelia-mesenchymal transitions

oa0001p016 | (1)

AR chromatin binding is reprogrammed in the absence of FOXA1 in ER- breast cancers

oa0001p017 | (1)

Loss of FAM3B promotes prostate cancer progression by modulating glucose metabolism

oa0001p018 | (1)

Assessing alterations in organelle contacts during prostate cancer development

oa0001p019 | (1)

Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene

oa0001p020 | (1)

Circular RNAs add further diversity to AR isoform repertoire

oa0001p021 | (1)

Estrogen receptor alpha controls gene expression via translational offsetting

oa0001p022 | (1)

Characterisation of developmental pathways that drive metastatic progression of breast cancer at single cell resolution

oa0001p023 | (1)

The Myoepithelium as a Risk Predictor in Ductal Carcinoma In Situ of the Breast

oa0001p024 | (1)

Lasofoxifene is an effective inhibitor of breast cancer lung and liver metastasis in a mammary intraductal (MIND) xenograft model of mutant ERα+ breast cancer

oa0001p025 | (1)

Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network

oa0001p026 | (1)

A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer progression

oa0001p027 | (1)

Estrogen maintains mammographic density via heparanase mediated induction of SDC-1 and -4

oa0001p028 | (1)

Immune signalling is a key driver of breast density and breast cancer risk

oa0001p029 | (1)

Translation of the ERα-PR crosstalk story to the clinic (the PIONEER study), and further preclinical exploration of the diverse role of progestins in ER-positive breast cancer

oa0001p030 | (1)

Androgen receptor binding sites are highly mutated in prostate cancer

oa0001p031 | (1)

New combination therapies for castration-resistant prostate cancer

oa0001p032 | (1)

Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration resistant prostate cancer

oa0001p033 | (1)

LobSig, a prognostic signature for ILC

oa0001p034 | (1)

Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer

oa0001p035 | (1)

Therapeutic targeting of Ezh2 enhances PD-1 blockade by induction of interferon gamma response

oa0001p036 | (1)

Lipid elongation in prostate cancer: an androgen regulated process and a novel therapeutic target

oa0001p037 | (1)

Novel role of CBFβ as a regulator of breast cancer phenotype, progression and metastasis

oa0001p038 | (1)

Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer

oa0001p039 | (1)

Quest for the lost andromedin

oa0001p040 | (1)

Unravelling the role of cell plasticity in BrCa development and metastasis

oa0001p041 | (1)

Extending genetic portraits of human prostate cancer

oa0001p042 | (1)

PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer

oa0001p043 | (1)

Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer

oa0001p044 | (1)

Epithelial mesenchymal transition, stromal density, and chemo-resistance in breast cancer (BrCa)

oa0001p045 | (1)

Single-cell transcriptomics reveals marked heterogeneity for intrinsic molecular subtype and cellular function in estrogen receptor positive breast cancer

oa0001p046 | (1)

A miR-194-regulated transcriptional network is associated with progression to androgen receptor-independent prostate cancer

oa0001p047 | (1)

IL6/STAT3 co-opts ER regulatory elements to drive metastasis in breast cancer

oa0001p048 | (1)

Exploring the clinical significance of interactions between oestrogen and progesterone receptors in breast and endometrioid adenocarcinomas by proximity ligation assay

oa0001p049 | (1)

DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer

oa0001p050 | (1)

Preclinical development of CDDD3-14, a potent and selective inhibitor of CDK4/6 for the treatment of breast cancer

oa0001p051 | (1)

Targeting HP1-alpha for prevention and treatment of neuroendocrine prostate cancer

oa0001p052 | (1)

Novel and highly selective CDK9 inhibitors suppress proliferation of triple negative breast cancer (TNBC) cells in vitro

Published by BioScientifica

Oncology Abstracts
ISSN 2631-4657 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more